MedTrace Logo

Risks of Bacterial and Fungal Superinfection in Patients With COVID-19

NCT05256316 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 790

Last updated 2023-05-22

No results posted yet for this study

Summary

Infection with bacteria or fungi can be deadly. Often, these types of infections can lead to an increase in the severity of illness requiring intensive care unit (ICU) admission, prolonged duration of treatment and further risks associated with additional infections and superinfections. These are also called hospital acquired secondary infections. Patients who contract COVID-19 and require an ICU admission are at increased risk of contracting these secondary infections, and receive certain medications that can lower your body's immune response. In COVID-19 patients who require these treatments, it is unclear what affect these medications can have on developing an additional infection as well as the rate of recovery/survival. This study is evaluating the effect these medications have on the development of secondary infections and rate of survival of COVID-19 patients that have been admitted to ICUs.

Conditions

Interventions

OTHER

Previously admitted COVID-19 patients in intensive care units

Exposure: this is a retrospective, observational study that does not include an intervention. Data collected for this study will be from previously hospitalized COVID-19 patients who had an intensive care unit stay during their admission

Sponsors & Collaborators

  • Merck Sharp & Dhome (Australia) Pty. Ltd.

    collaborator UNKNOWN

  • Christian Medical College, Vellore, India

    collaborator OTHER

  • Tan Tock Seng Hospital

    collaborator OTHER

  • Royal Brisbane and Women's Hospital

    collaborator OTHER_GOV

  • Siriraj Hospital

    collaborator OTHER

  • University of North Carolina, Chapel Hill

    collaborator OTHER

  • The University of Queensland

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-14
Primary Completion
2022-12-04
Completion
2022-12-04

Countries

  • United States
  • Australia
  • India
  • Singapore
  • Thailand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05256316 on ClinicalTrials.gov